Search Clinical Trials
Our researchers are currently in need of adult and pediatric study participants to help us pursue better treatments and cures. Participants may receive medical evaluations and procedures, study medication, disease-related education and possible financial compensation for time, travel and participation.
Select a Condition or Specialty
- Allergy
- Alpha-1 Antitrypsin Deficiency
- Asthma
- Cardiology
- Chronic Obstructive Pulmonary Disease (COPD)
- COVID-19 (Coronavirus)
- Cystic Fibrosis
- Eczema (Atopic Dermatitis)
- Environmental & Occupational Health
- Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- Food Allergy
- Gastroenterology
- Idiopathic Pulmonary Fibrosis (IPF)
- Interstitial Lung Disease (Pulmonary Fibrosis)
- Lung Cancer
- Oncology
- Pulmonary Hypertension (PH)
- Respiratory (Pulmonary)
- Rheumatology
- Sarcoidosis
- Sleep
All Clinical Trials
Discovering New Ways to Treat Modulator-Ineligible CF
The REACH Study is a long-term, observational study aiming to gather high-quality data on people with cystic fibrosis (CF) who cannot benefit from CFTR modulators. By collecting core data, REACH will help develop and assess future therapies for this population.
- Gender
- Any
- Ages
- 12+
- Compensation
- Provided
- Time Required
- 4 clinic visits over the course of a year, at enrollment, 3 months, 6 months and 12 months.
CMTX-101: IV Treatment of P. aeruginosa in Combination with Inhaled Antibiotics
People with cystic fibrosis (CF) are more vulnerable to a wide variety of bacterial infections in their lungs. One of these bacteria, Pseudomonas aeruginosa, can cause infections that decrease lung function over time. Researchers are evaluating a new therapy that may help people with CF more effectively clear these infections.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Seven clinic visits over approximately 35 days. Total study duration includes up to 60 days of screening.
Possible New Treatment for CF and NTM
Researchers in the ABATE Study are testing the safety of a drug called gallium nitrate for people with cystic fibrosis (CF) who also have been diagnosed with nontuberculous mycobacteria (NTM).
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- 8 in-person visits, including two 5-day inpatient stays, and 4 phone calls over 28 weeks
BEACON-CF: Investigational mRNA Therapy for Cystic Fibrosis
For many people living with cystic fibrosis, there are treatments available called cystic fibrosis transmembrane conductance regulator (CFTR) modulators that can help treat the underlying cause of cystic fibrosis. However, more than 5,000 people living with cystic fibrosis have a change in both of their CFTR genes that makes them not expected to benefit from CFTR modulators.
- Gender
- Any
- Ages
- 18-65
- Compensation
- Provided
- Time Required
- 28 weeks with 8 in-person visits and 4 phone calls.
Investigational Gene Therapy for Adults with CF
Adults with Cystic Fibrosis who are unable to take CFTR modulators are being asked to participate in a clinical trial for an investigational gene therapy drug known as 4D-710.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- 24 months
Exploring How Parenthood Impacts Cystic Fibrosis Patients
A growing number of people with cystic fibrosis (CF) are considering parenthood. CF specialists recognize that there is a need to better support first-time parents and need input from them.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Five years, one in person visit for enrollment, followed by surveys that can be completed remotely. Four surveys are needed during the first year, then two surveys per year for years 2-5.
Adult Trials
Discovering New Ways to Treat Modulator-Ineligible CF
The REACH Study is a long-term, observational study aiming to gather high-quality data on people with cystic fibrosis (CF) who cannot benefit from CFTR modulators. By collecting core data, REACH will help develop and assess future therapies for this population.
- Gender
- Any
- Ages
- 12+
- Compensation
- Provided
- Time Required
- 4 clinic visits over the course of a year, at enrollment, 3 months, 6 months and 12 months.
BEACON-CF: Investigational mRNA Therapy for Cystic Fibrosis
For many people living with cystic fibrosis, there are treatments available called cystic fibrosis transmembrane conductance regulator (CFTR) modulators that can help treat the underlying cause of cystic fibrosis. However, more than 5,000 people living with cystic fibrosis have a change in both of their CFTR genes that makes them not expected to benefit from CFTR modulators.
- Gender
- Any
- Ages
- 18-65
- Compensation
- Provided
- Time Required
- 28 weeks with 8 in-person visits and 4 phone calls.
Investigational Gene Therapy for Adults with CF
Adults with Cystic Fibrosis who are unable to take CFTR modulators are being asked to participate in a clinical trial for an investigational gene therapy drug known as 4D-710.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- 24 months
Exploring How Parenthood Impacts Cystic Fibrosis Patients
A growing number of people with cystic fibrosis (CF) are considering parenthood. CF specialists recognize that there is a need to better support first-time parents and need input from them.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Five years, one in person visit for enrollment, followed by surveys that can be completed remotely. Four surveys are needed during the first year, then two surveys per year for years 2-5.
Pediatric Trials
Discovering New Ways to Treat Modulator-Ineligible CF
The REACH Study is a long-term, observational study aiming to gather high-quality data on people with cystic fibrosis (CF) who cannot benefit from CFTR modulators. By collecting core data, REACH will help develop and assess future therapies for this population.
- Gender
- Any
- Ages
- 12+
- Compensation
- Provided
- Time Required
- 4 clinic visits over the course of a year, at enrollment, 3 months, 6 months and 12 months.